- IMPORTANT! Request for ACTION on #CBD #CBDOil – #CBDSaves! Please SHARE!
- #CBD Shows Hope for #diabetes #Fibromyalgia #IBS & #migraine LegalHerbalShop.com
- Worried about #Kratom effects on your organs? #Liver? #Kidneys? #Kratom Saves
- Is #CBD a Cure for #Cancer? #CBDoil
- We Need Your HELP to Save #Kratom #AKA #IAMKRATOM #KRATOM SAVES
- September 2017
- June 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- December 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- June 2013
- May 2013
- September 2012
- August 2012
- June 2012
- May 2012
- March 2012
- February 2012
- December 2010
- October 2010
- September 2010
- acid reflux
- alternative medicine
- anti cancer
- bath salts
- BIG PHARMA
- cancer treatments
- Chronic Fatigue Syndrome
- decriminalize drugs
- heart burn
- Herbal Incense Blends
- herbal medicine
- herbal supplements
- Kra Thum khok
- Legal Bud
- legal highs
- legalize marijuana
- LYME DISEASE
- medicinal marijuana
- mitragyna speciosa
- natural healing
- PAIN MANAGMENT
- Spice K2
- vaccine truth
- whole foods
This PETITION takes just seconds to sign. It is meant to complement, not replace, other efforts. Please share this far and wide.
Also, please consider a donation to the AKA. Click HERE to donate.
We know it is the holiday season, money is tight, many of you have already donated. However, Just $5.00 dollars would be helpful, if everyone that receives this email donates, if everyone that you share it to gives $5.00…. we would be a long ways towards our needed amount. Just think, it could be YOUR $5.00 that WINS this fight! Do it as an anonymous gift for someone you care about.
This information brought to you by: www.legalherbalshop.com
From the DRUG POLICY ALLIANCE:
Last month, you were one of tens of thousands to message Congress about the DEA’s absurd decision to place kratom, a medicinal plant used for millennia in Southeast Asia and currently used by millions in the U.S., on the list of Schedule I substances.
I must admit, even after we sent over 70,000 messages to Congress, and placed thousands of phone calls, I didn’t think the DEA would back down. They never have before.
Finally, in an unprecedented move, the DEA blinked. This morning, the DEAwithdrew its plan to ban kratom from the federal register, and opened up kratom scheduling to public comment through December 1st.
It’s truly remarkable to see the DEA, an agency with a long track record of ignoring both science and public opinion, forced to reconsider their actions.
It was the advocacy of people like you that spurred 51 Representatives and almost a dozen Senators to ask the DEA to postpone its plan to ban kratom.
But the fight isn’t over. We only have until December 1st to submit public comments to the DEA, and if they think the public outcry has died down, they’ll try to place kratom in Schedule I again.
Comments can be submitted through regulations.gov, though as of this afternoon comments have yet to open. Check back soon, and we’ll be sure to email you again once they are.
Thanks for your help in this fight — together we’ve accomplished something unprecedented. If you can, please chip in $25 or more to help us continue dismantling the drug war, one law at a time.
The DEA Has Withdrawn It’s Notice of Intent to Ban Kratom For Now.
On August 31, 2016, DEA published in the Federal Register, a notice of its intent to place mitragynine and 7-hydroxymitragynine, two substances of the plant Mitragyna speciosa also referred to as kratom, in Schedule I. Since publishing that notice, the DEA has received a number of comments from members of the public. Some of the commenters offered their opinions regarding the pharmacological effects of mitragynine and 7-hydroxymitragynine. To allow consideration of these comments, as well as others, the DEA has withdrawn its notice of intent to temporarily place Schedule I controls on Kratom and is soliciting public comments until December 1, 2016.
The DEA has also asked the Food and Drug Administration (FDA) to expedite its scientific and medical evaluation and scheduling recommendation for these substances, which the DEA previously requested.
With respect to mitragynine and 7-hydroxymitragynine, the DEA will consider all public comments received under the above procedures, as well as the FDA’s scientific and medical evaluation and scheduling recommendation for these substances. Once the DEA has received and considered all of this information, the DEA will decide whether to proceed with scheduling of mitragynine and 7-hydroxymitragynine pursuant to the requirements of the Controlled Substances Act.
The DEA’s withdrawal notice and solicitation of comments may be found here:https://www.federalregister.gov/documents/2016/10/13/2016-24659/schedules-of-controlled-substances-temporary-placement-of-mitragynine-and-7-hydroxymitragynine-into
It looks like it will be published today or tomorrow.
Thank you everyone for there hard work. We will need to keep on this hard if we plan to win this next stage of keeping Kratom legal.
Would you look at that. #Kratom might help cure #cancer. There is research in progress. #SAVEKRATOM #KRATOMSAVESLIVES
Antioxidant value and antiproliferative efficacy of mitragynine and a silane reduced analogue.
Goh TB, et al. Asian Pac J Cancer Prev. 2014.
BACKGROUND: To investigate the antioxidant value and anticancer functions of mitragynine (MTG) and its silane-reduced analogues (SRM) in vitro.
MATERIALS AND METHODS: MTG and SRM was analyzed for their reducing power ability, ABTS radical inhibition and 1,1-diphenyl-2-picryl hydrazylfree radicals scavenging activities. Furthermore, the antiproliferation efficacy was evaluated using MTT assay on K 562 and HCT116 cancer cell lines versus NIH/3T3 and CCD18-Co normal cell lines respectively.
RESULTS: SRM and MTG demonstrate moderate antioxidant value with ABTS assay (Trolox equivalent antioxidant capacity (TEAC): 2.25±0.02 mmol trolox / mmol and 1.96±0.04 mmol trolox / mmol respectively) and DPPH (IC50=3.75±0.04 mg/mL and IC50=2.28±0.02 mg/mL respectively). Both MTG and SRM demonstrate equal potency (IC50=25.20±1.53 and IC50= 22.19±1.06 respectively) towards K 562 cell lines, comparable to control, betulinic acid (BA) (IC5024.40±1.26). Both compounds showed concentration-dependent cytototoxicity effects and exert profound antiproliferative efficacy at concentration > 100 μM towards HCT 116 and K 562 cancer cell lines, comparable to those of BA and 5-FU (5-Fluorouracil). Furthermore, both MTG and SRM exhibit high selectivity towards HCT 116 cell lines with selective indexes of 3.14 and 2.93 respectively compared to 5-FU (SI=0.60).
CONCLUSIONS: These findings revealed that the medicinal and nutitional values of mitragynine obtained from ketum leaves that growth in tropical forest of Southeast Asia and its analogues does not limited to analgesic properties but could be promising antioxidant and anticancer or chemopreventive compounds.